Curanter

Curanter Therapeutics is a pre-clinical stage biotechnology company focused on the discovery and development of novel small molecule inhibitors for oncology. The company's primary research efforts target Ubiquitin-specific protease 7 (USP7), a deubiquitinating enzyme that plays a pivotal role in regulating the stability of key tumor suppressors and oncogenes. By selectively inhibiting USP7, Curanter aims to restore natural apoptotic pathways in cancer cells, particularly those where p53 function is compromised. Leveraging structural biology and advanced medicinal chemistry, the company is building a pipeline of potent inhibitors to address unmet needs in solid tumors and hematological malignancies.